Do topical calcineurin inhibitors treat hypopigmentation?

Hypopigmentation describes skin that is lighter than the surrounding area, rather than one single disease. It can follow inflammation, irritation, infection, injury or other pigment changes. A topical calcineurin inhibitor works on local immune activity, so it is most relevant when inflammation is part of the process. It cannot correct lighter skin caused by a scar or by loss of pigment cells without an inflammatory target. Colour often returns gradually after the underlying irritation settles, and the timing varies by cause and skin site.

Ask a clinician to examine new, spreading or sharply defined pale patches before treating them. If the medicine is prescribed, use a thin layer as directed and stop adding new fragranced products to the area. Moisturise dry skin and protect the patch and surrounding skin from sun exposure, because tanning around it can make the contrast more visible. Take occasional photographs in similar light to show whether the edges, scale or colour are changing.

Seek review if a patch is enlarging quickly, itchy, scaly, painful, numb, bleeding or associated with hair colour change. Contact the prescriber if application causes persistent burning, swelling, blistering or worsening redness. A prompt assessment is also sensible when several new patches appear or when the change follows a new medicine, chemical or injury.

Ask what is causing the hypopigmentation, whether inflammation is present, what improvement would look like, and when colour should be reassessed. Confirm how to combine treatment with moisturiser and sun protection, and which changes mean the diagnosis should be reconsidered.